Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Published on Jun 7, 2019in Frontiers in Immunology5.085
· DOI :10.3389/FIMMU.2019.01296
Kevin O. Saunders26
Estimated H-index: 26
(Duke University)
Sources
Abstract
Antibodies and Fc-fusion antibody-like proteins have become successful antibody-based biologics developed for cancer treatment, passive immunity against infection, addiction, and autoimmune diseases. In general these biopharmaceuticals can be used for blocking protein:protein interactions, crosslinking host receptors to induce signaling, recruiting effector cells to targets, and fixing complement. With the vast capability of antibodies to affect infectious and genetic diseases much effort has been placed on improving and tailoring antibodies for specific functions. While antibody:antigen engagement is critical for an efficacious antibody biologic, equally as important are the hinge and constant domains of the heavy chain. It is the hinge and constant domains of the antibody that engage host receptors or complement protein to mediate a myriad of effector functions and regulate antibody circulation. Molecular and structural studies have provided insight into how the hinge and constant domains from antibodies across different species, isotypes, and subclasses are recognized by host cell receptors and complement protein C1q. The molecular details of these interactions have led to manipulation of the sequences and glycosylation of hinge and constant domains to enhance or reduce antibody effector functions and circulating half-life. This review will describe the concepts being applied to optimize the hinge and crystallizable fragment of antibodies, and it will detail how these interactions can be tuned up or down to mediate a biological function that confers a desired disease outcome.
Figures & Tables
Download
📖 Papers frequently viewed together
1,096 Citations
200917.54Blood
7 Authors (Pierre Bruhns, ..., Marc Daëron)
988 Citations
17 Citations
References174
Newest
#1Michihiko Aoyama (NIH: National Institutes of Health)H-Index: 2
#1Michihiko AoyamaH-Index: 4
Last. Akiko Ishii-WatabeH-Index: 24
view all 9 authors...
ABSTRACTTypical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G...
12 CitationsSource
#1Marina Caskey (Rockefeller University)H-Index: 38
#2Florian Klein (University of Cologne)H-Index: 32
Last. Michel C. Nussenzweig (Rockefeller University)H-Index: 172
view all 3 authors...
Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-lived latent reservoir of integrated proviruses. Therefore, ART must be administered on a life-long basis. Here we review recent preclinical and clinical studies suggesting that immunotherapy may be an alternative or an adjuvan...
109 CitationsSource
#1Felix Sim (Barwon Health)H-Index: 3
#2Rom Leidner (Providence Portland Medical Center)H-Index: 20
Last. R.B. Bell (Providence Portland Medical Center)H-Index: 3
view all 3 authors...
: The immune system has a vital role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). Immune evasion of cancer cells leads to progression of HNSCC. An understanding of this mechanism provides the basis for improved therapies and outcomes for patients. Through the tumor's influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. This article provides an overview of the interaction betw...
15 CitationsSource
#1Tae Hyun Kang (University of Texas at Austin)H-Index: 11
#2Chang-Han Lee (University of Texas at Austin)H-Index: 12
Last. George GeorgiouH-Index: 100
view all 10 authors...
IgG antibodies mediate the clearance of target cells via the engagement of Fc gamma receptors (FcγRs) on effector cells by eliciting antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively). Because (i) the IgG Fc domain binds to multiple FcγRs with varying affinities; (ii) even low Fc:FcγRs affinity interactions can play a significant role when antibodies are engaged in high avidity immune complexes and (iii) most effector cells express multiple FcγRs, the clearan...
6 CitationsSource
#1Ryuta Wada (Astellas Pharma)H-Index: 1
#2Makoto Matsui (Astellas Pharma)H-Index: 1
Last. Nana Kawasaki (YCU: Yokohama City University)H-Index: 36
view all 3 authors...
ABSTRACTGlycosylation of the conserved asparagine residue in each heavy chain of IgG in the CH2 domain is known as N-glycosylation. It is one of the most common post-translational modifications and...
52 CitationsSource
ABSTRACTFor the past 10 years, the annual ‘Antibodies to watch’ articles have provided updates on key events in the late-stage development of antibody therapeutics, such as first regulatory review ...
265 CitationsSource
#1Mathilde Bas (French Institute of Health and Medical Research)H-Index: 1
#2Aurélie TerrierH-Index: 4
Last. Céline MonnetH-Index: 14
view all 17 authors...
The long serum t 1/2 of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. Fc glycosylation is thought not to influence FcRn binding and IgG longevity in vivo. In this article, we demonstrate that hypersialylation of asparagine 297 (N297) enhances IgG serum persistence. This polarized glycosylation is achieved using a novel Fc mutation, a glutamate residue deletion at position 294 (Del) that endows IgGs with an up to 9-fo...
22 CitationsSource
#1Bosco Paes (McMaster University)H-Index: 49
#2Doyoung Kim (Sunnybrook Health Sciences Centre)H-Index: 3
Last. Krista L. Lanctôt (Sunnybrook Health Sciences Centre)H-Index: 73
view all 6 authors...
An observational study was conducted of children < 2 years who received ≥ 1 dose of palivizumab in 32 Canadian institutions from 2005 to 2017. We compared respiratory illness (RIH) and respiratory syncytial virus-related hospitalization (RSVH) hazards in children with a congenital airway anomaly (CAA) versus those prophylaxed for standard indications (SI) and serious medical disorders (SMD). Data were assembled on neonatal course, demographics, palivizumab utilization and adherence, and respirat...
3 CitationsSource
#1Marcela Helena Gambim Fonseca (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 1
#2Gilvan Pessoa Furtado (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 11
Last. Carla F. C. Fernandes (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 12
view all 5 authors...
Abstract Due mainly to their high level of affinity and specificity, therapeutic monoclonal antibodies (mAbs) have been frequently selected as treatment for cancer, autoimmune or chronic inflammatory diseases. Despite the increasing number of mAbs and related products in the biopharmaceutical market, they are still expensive, can cause undesired side effects, and eventually cause resistance. Antibody engineering, which emerged to overcome limitations faced by mAb therapy, has supported the devel...
14 CitationsSource
#1Pilar Mendoza (Rockefeller University)H-Index: 14
#2Henning GruellH-Index: 17
Last. Michel C. Nussenzweig (Rockefeller University)H-Index: 172
view all 36 authors...
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg−1 of each antibody at 0, 3 and 6 wee...
222 CitationsSource
Cited By77
Newest
#1Henri Gonde (French Institute of Health and Medical Research)H-Index: 2
#2Mélanie Demeules (French Institute of Health and Medical Research)H-Index: 2
Last. Sahil Adriouch (French Institute of Health and Medical Research)H-Index: 26
view all 0 authors...
On murine T cells, mono-ADP ribosyltransferase ARTC2.2 catalyzes ADP-ribosylation of various surface proteins when nicotinamide adenine dinucleotide (NAD+) is released into the extracellular compartment. Covalent ADP-ribosylation of the P2X7 receptor by ARTC2.2 thereby represents an additional mechanism of activation, complementary to its triggering by extracellular ATP. P2X7 is a multifaceted receptor that may represents a potential target in inflammatory, and neurodegenerative diseases, as wel...
Source
#1Patricia Gogesch (Paul Ehrlich Institute)H-Index: 3
#2Simone Dudek (Paul Ehrlich Institute)H-Index: 1
Last. Martina Anzaghe (Paul Ehrlich Institute)H-Index: 6
view all 0 authors...
Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indications. In order to ensure clinical efficacy and safety aspects, (pre-)clinical experimental approaches evaluate the respective modes of action (MoA). In addition to antigen-specificity including binding affinity and -avidity, MoA comprise Fc-mediated e...
Source
#1Dapeng Li (Duke University)H-Index: 8
#1Dapeng Li (Duke University)H-Index: 17
Last. Laura L. Sutherland (Duke University)H-Index: 28
view all 64 authors...
Summary null null SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs als...
4 CitationsSource
Therapeutic mAbs have dominated the class of immunotherapeutics in general and immune checkpoint inhibitors in particular. The high specificity of mAbs to the target molecule as well as their extended half-life and (or) the effector functions raised by the Fc part are some of the important aspects that contribute to the success of this class of therapeutics. Equally potential candidates are decoys and their fusions that can address some of the inherent limitations of mAbs, like immunogenicity, r...
Source
#1Shee Kwan Phung (UMN: University of Minnesota)
#2Jeffrey S. Miller (UMN: University of Minnesota)H-Index: 91
Last. Martin Felices (UMN: University of Minnesota)H-Index: 26
view all 3 authors...
Natural killer (NK) cell-mediated cancer immunotherapy has grown significantly over the past two decades. More recently, multi-specific engagers have been developed as cancer therapeutics to effectively arm endogenous NK cells to more potently induce specific cytolytic responses against tumor targets. This review explores the bi- and tri-specific NK/tumor engagers that are emerging as a new generation of immunotherapeutics. These molecules vary in configuration, but they typically have small mol...
Source
#2Xiaohua Hao (Capital Medical University)
Last. Li Yan
view all 12 authors...
Abstract null Background null BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal neutralizing antibodies with modified Fc region that extends half-life and are being developed as cocktail therapy for the treatment of COVID-19. Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 were investigated in healthy adults. null Methods null Single ascending doses of BRII-196 and BRII-198 were evaluated in parallel in the first-in-human, placebo-controlled phase 1 stu...
Source
#1Eric A. StoneH-Index: 50
Last. Ashley GrasH-Index: 1
view all 25 authors...
Anti-CTLA-4 antibodies such as ipilimumab were among the first immune-oncology agents to show significantly improved outcomes for patients. However, existing anti-CTLA-4 therapies fail to induce a response in a majority of patients and can induce severe, immune-related adverse events. It has been assumed that checkpoint inhibition, i.e., blocking the interaction between CTLA-4 and its ligands, is the primary mechanism of action for ipilimumab. In this study we present evidence that checkpoint in...
Source
#1Xiangkun Yang (Regeneron)
#2Haeri Seol (Regeneron)
Last. Ning Li (Regeneron)H-Index: 6
view all 7 authors...
Antibody-drug conjugates (ADCs) are biopharmaceuticals for the targeted delivery of antitumor agents. ADCs can be highly heterogeneous with various drug-to-antibody ratio (DAR) species, conjugation sites, and occupancy levels. The conjugation site can modulate the ADC stability and efficacy and therefore can be considered to be a critical quality attribute (CQA) during development. Traditional mass spectrometry (MS)-based peptide mapping methods cannot accurately quantify site-specific conjugati...
Source
#1Thomas Tarenzi (University of Trento)
#1Tarenzi T (University of Trento)
Last. Raffaello Potestio (University of Trento)H-Index: 20
view all 3 authors...
The affinity of an antibody for its antigen is primarily determined by the specific sequence and structural arrangement of the complementarity-determining regions (CDRs). Recently, however, evidence has accumulated that points toward a nontrivial relation between the CDR and distal sites on the antibody structure: variations in the binding strengths have been observed upon mutating amino acids separated from the paratope by several nanometers, thus suggesting the existence of a communication net...
Source
#1Tomohiro Kotaki (RMIT: RMIT University)H-Index: 9
#2Takeshi Kurosu (NIH: National Institutes of Health)H-Index: 18
Last. Benjamin J. DoranzH-Index: 53
view all 13 authors...
Dengue virus (DENV), from the genus flavivirus of the family flaviviridae, causes serious health problems globally. Human monoclonal antibodies (HuMAb) can be used to elucidate the mechanisms of neutralization and antibody-dependent enhancement (ADE) of DENV infections, leading to the development of a vaccine or therapeutic antibodies. Here, we generated eight HuMAb clones from an Indonesian patient infected with DENV. These HuMAbs exhibited the typical characteristics of weak neutralizing antib...
Source